drug · small molecule
axitinib SR
Marketedupdated 3mo agoby $OCUL OCULAR THERAPEUTIX, INC🔗 ChEMBL
Approvedcommunity read0 votes
🐶 often sniffed alongside
top 3Small molecule drug with a maximum clinical stage of Approval (across all indications), with an approval for renal cell carcinoma and neoplasm and 33 investigational indications.
targets
Vascular endothelial growth factor receptor
all catalysts(1)
Trials studying axitinib SR
- phase2A Study of AK104 Monotherapy or AK104 Plus Axitinib in Advanced/Metastatic Renal Cell Carcinoma
- phase1Study of PF-07265807 in Participants With Metastatic Solid Tumors.
- phase2Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
- phase2SLM + Axitinib for Clear Cell RCC
- phase2Axitinib Monotherapy With Early Dynamic Contrast Enhanced Ultrasound Monitoring in Chemorefractory Third Line Metastatic Colorectal Cancer
- phase3Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
- phase1A Study to Evaluate the Bioavailability of Pembrolizumab (MK-3475) Via Subcutaneous (SC) Injection of Pembrolizumab Formulated With Berahyaluronidase Alfa (MK-5180) [MK-3475A] In Advanced Solid Tumors (MK-3475A-C18)
- phase2Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)
Patent cliff
source: FDA Orange Bookfirst barrier falls
Dec 14, 2030
~4.3 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (16)
- Jul 12, 2037patentUS 10869924*PED
- Jul 12, 2037patentUS 10869924*PED
- Jan 12, 2037method-of-use (U-3044)US 10869924
- Jan 12, 2037method-of-use (U-3044)US 10869924
- Aug 3, 2035patentUS 10570202*PED
- Aug 3, 2035patentUS 10570202*PED
- Aug 3, 2035patentUS 12534530*PED
- Aug 3, 2035patentUS 12534530*PED
- Feb 3, 2035method-of-use (U-2844)US 10570202
- Feb 3, 2035method-of-use (U-2844)US 10570202
- Feb 3, 2035method-of-use (U-4412)US 12534530
- Feb 3, 2035method-of-use (U-4412)US 12534530
- Jun 14, 2031patentUS 8791140*PED4.8y
- Jun 14, 2031patentUS 8791140*PED4.8y
- Dec 14, 2030compositionUS 87911404.3y
- Dec 14, 2030compositionUS 87911404.3y
News(1)
- EyePoint’s Phase 3 fail sends stock spiraling amid next-gen AMD raceEyePoint’s quest to reduce treatment burden for patients with age-related macular degeneration has hit a bump in the road, with a clinical miss driving the biotech’s stock down by 70%.biospace · 19h ago
Data sources
last refreshed 14m ago
Found something off?
comments(0)
5-min edit window · permanent after that